Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence

Current Gastroenterology Reports

Volumn 19, Issue 8, 2017, Pages

  Rank, Kevin M ^a   Shaukat, Aasma ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Advanced adenoma; Colorectal cancer; Fit; gFOBT; hsFOBT; mtsDNA; Screening

Indexed keywords

ADVANCED CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COHORT ANALYSIS; COLON ADENOMA; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; FECAL IMMUNOCHEMICAL TESTING; FECES ANALYSIS; HUMAN; MULTITARGET DNA STOOL TESTING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; COLORECTAL TUMOR; FECES; OCCULT BLOOD;

DNA; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GUAIAC;

COLORECTAL NEOPLASMS; DNA, NEOPLASM; FECES; GUAIAC; HUMANS; INDICATORS AND REAGENTS; OCCULT BLOOD;

EID: 85025111105     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-017-0579-4     Document Type: Review

References (37)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
2. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use—United States, 2012. MMWR. 2013;62(44):881.
3. DeBourcy AC, Lichtenberger S, Felton S, Butterfield KT, Ahnen DJ, Denberg TD. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med. 2008;23(2):169–74.
4. Inadomi JM, Vijan S, Janz NK, Fagerlin A, Thomas JP, Lin YV, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575–82.
5. Levin TR. Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. Gastrointest Endosc. 2016;83(3):552–4.
6. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91(5):434–7.
7. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–14.
8. Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW. Fecal occult blood screening for colorectal cancer in the general population results of a controlled trial. Cancer. 1986;58(2):397–403.
9. • Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016. This article provides a concise and relevant set of recommendations regarding FIT testing and addresses several technical questions regarding test characteristics, advantages and shortcomings and practical questions regarding implementation of FIT testing in a practice environment.
10. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126(7):1674–80.
11. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–71.
12. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008;95(8):1029–36.
13. Malila N, Palva T, Malminiemi O, Paimela H, Anttila A, Hakulinen T, et al. Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland. J Med Screen. 2011;18(1):18–23.
14. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2011:gutjnl-2011.
15. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334(3):155–60.
16. Levi Z, Birkenfeld S, Vilkin A, Bar-Chana M, Lifshitz I, Chared M, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128(10):2415–24.
17. Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99(19):1462–70.
18. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441–50.
19. Fenton JJ, Elmore JG, Buist DS, Reid RJ, Tancredi DJ, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med. 2010;8(5):397–401.
20. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med. 2008;149(9):638–58.
21. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood–. The fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer. 1980;45(S5):1099–102.
22. Allison JE. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014;8(2):117–30.
23. Levy BT, Bay C, Xu Y, Daly JM, Bergus G, Dunkelberg J, et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen. 2014;21(3):133–43.
24. Tao S, Seiler CM, Ronellenfitsch U, Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol. 2013;52(8):1667–75.
25. •• Lin JS, Piper M, Perdue LA. Screening for colorectal cancer: a systematic review for the US Preventive Services Task Force: evidence synthesis no. 135. Rockville, MD: Agency for Healthcare Research and Quality. 2016. This study provides the most comprehensive summary of information regarding screening tests for colonoscopy and is a highly inclusive reference for specific questions.
26. Zorzi M, Fedeli U, Schievano E, Bovo E, Guzzinati S, Baracco S, et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015;64(5):784–90.
27. Chiu HM, Lee YC, Tu CH, Chen CC, Tseng PH, Liang JT, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013;11(7):832–8.
28. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171–81.
29. Cheng TI, Wong JM, Hong CF, Cheng SH, Cheng TJ, Shieh MJ, et al. Colorectal cancer screening in asymptomatic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc. 2002;101(10):685–90.
30. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Sakaguchi K, et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol. 2007;102(10):2259–64.
31. Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2016.
32. Plumb AA, Halligan S, Pendsé DA, Taylor SA, Mallett S. Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: systematic review and meta-analysis. Eur Radiol. 2014;24(5):1049–58.
33. Lin JS, Webber EM, Beil TL, Goddard KA, Whitlock EP. Fecal DNA testing in screening for colorectal cancer in average-risk adults.
34. • Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. New England Journal of Medicine. 2014;370(14):1287–97. A large study and the most comprehensive validation of mtsDNA provides good perspective on advantages and disadvantages of testing and potential implications of mtsDNA testing
35. Robertson DJ, Dominitz JA. Stool DNA and colorectal-cancer screening. N Engl J Med. 2014;370(14):1350.
36. Lee JK, Levin TR, Corley DA. The road ahead: what if gastroenterologists were accountable for preventing colorectal cancer? Clin Gastroenterol Hepatol. 2013;11(3):204.
37. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011:mxr007.